Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial
- PMID: 17591024
Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial
Abstract
Objective: We conducted a multicentre, double-blind, placebo-controlled, randomized study to investigate the efficacy of 2-year lamivudine treatment in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.
Methods: One-hundred-and-thirty-nine treatment-naive patients with HBeAg-negative chronic hepatitis B were randomized to receive either lamivudine (100 mg daily) or placebo in a 2:1 ratio for 24 months and were followed for an additional 6 months. The primary endpoint was complete response, defined as hepatitis B virus (HBV) DNA < 10,000 copies/ml and normalization of alanine aminotransferase (ALT) levels at month 24.
Results: On intent-to-treat analysis at month 24, significantly more patients in the lamivudine group than in the placebo group had complete response (56% and 11%, respectively; P < 0.001) or negative HBV DNA (26% and 6%, respectively; P = 0.006). After adjustment of baseline HBV DNA and ALT, the odds ratio for complete response of the lamivudine group versus the placebo group was 10.8 (95% confidence interval: 3.8-30.2; P < 0.001). The median log HBV DNA reduction was 3.21 copies/ml for the lamivudine group compared with 0.47 copies/ml for the placebo group (P < 0.001). Genotypic resistance was detected in 23% and 31% of patients in the lamivudine group at months 12 and 24, respectively. Negative HBV DNA at month 6 was associated with high complete response (84%) and low drug resistance (1%) at month 24. At month 30, there was no difference between lamivudine and placebo groups in the rates of complete response (26% vs 19%, respectively; P = 0.38) or negative HBV DNA (10% vs 2%, respectively; P = 0.09).
Conclusions: Two-year lamivudine treatment is effective in HBeAg-negative chronic hepatitis B. However, the response is not sustained after treatment cessation.
Similar articles
-
Lamivudine as initial treatment for chronic hepatitis B in the United States.N Engl J Med. 1999 Oct 21;341(17):1256-63. doi: 10.1056/NEJM199910213411702. N Engl J Med. 1999. PMID: 10528035 Clinical Trial.
-
[Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].Zhonghua Gan Zang Bing Za Zhi. 2009 Aug;17(8):564-8. Zhonghua Gan Zang Bing Za Zhi. 2009. PMID: 19719911 Chinese.
-
Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.Antivir Ther. 2009;14(5):679-85. Antivir Ther. 2009. PMID: 19704171 Clinical Trial.
-
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Gastroenterology. 2004 Jan;126(1):91-101. doi: 10.1053/j.gastro.2003.10.051. Gastroenterology. 2004. PMID: 14699491 Clinical Trial.
-
Lamivudine. A review of its therapeutic potential in chronic hepatitis B.Drugs. 1999 Jul;58(1):101-41. doi: 10.2165/00003495-199958010-00015. Drugs. 1999. PMID: 10439933 Review.
Cited by
-
Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues.Hepatol Int. 2008 Jun;2(2):163-78. doi: 10.1007/s12072-008-9061-6. Epub 2008 Mar 4. Hepatol Int. 2008. PMID: 19669301 Free PMC article.
-
Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma.World J Hepatol. 2015 Jul 8;7(13):1742-54. doi: 10.4254/wjh.v7.i13.1742. World J Hepatol. 2015. PMID: 26167247 Free PMC article. Review.
-
Hepatitis B Virus: From Diagnosis to Treatment.Pol J Microbiol. 2020 Dec;69(4):391-399. doi: 10.33073/pjm-2020-044. Epub 2020 Dec 27. Pol J Microbiol. 2020. PMID: 33574867 Free PMC article. Review.
-
Economic evaluation of treatments for chronic hepatitis B.Braz J Infect Dis. 2013 Jul-Aug;17(4):418-26. doi: 10.1016/j.bjid.2012.12.005. Epub 2013 Jul 10. Braz J Infect Dis. 2013. PMID: 23849851 Free PMC article.
-
Molecular cancer prevention: Current status and future directions.CA Cancer J Clin. 2015 Sep-Oct;65(5):345-83. doi: 10.3322/caac.21287. Epub 2015 Aug 18. CA Cancer J Clin. 2015. PMID: 26284997 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical